The World Health Organization (WHO) announced on Thursday the emergency approval of the Convidecia vaccine from the Chinese company CanSino Biologics.
The vaccine is given in a single dose and is recommended by the WHO for all age groups starting at age 18, according to a statement from the organization.
The vaccine that the company CanSIno Biologics developed — in partnership with the Institute of Biology of the Chinese Academy of Military Medical Sciences — is called Convidecia, but it is better known as Ad5-nCoV.
This substance is based on an adenovirus called Ad5, and therefore its name. It is a type of virus that under natural conditions causes respiratory diseases such as the common flu. But in this case, CanSino scientists modified that Ad5 to turn it into a vector that will carry a part of SARS-COV-2 inside the human body, to generate an immune response.
At first CanSino proposed a single dose scheme, but in August the same pharmaceutical company issued a statement in which it recommended in Mexico a second application of the vaccine six months after the first, to multiply the antibodies and offer greater protection.
CanSino joins the list of vaccines approved by the WHO with Pfizer-BioNTech, Moderna, Johnson & Johnson, AstraZeneca, Bharat Biotech, Novavax, Sinovac and Sinopharm.
In Mexico, the Federal Commission for the Protection against Sanitary Risks (Cofepris) authorized the Cansino vaccine for emergency use since February 2021.
I share with you that, at last, WHO approved the CANSINO vaccine against COVID-19 https://t.co/ycOUdWqng6
— Marcelo Ebrard C. (@m_ebrard) May 19, 2022
What we do at Animal Político requires professional journalists, teamwork, dialogue with readers and something very important: independence. You can help us keep going. Be part of the team.
Subscribe to Animal Político, receive benefits and support free journalism.#YoSoyAnimal
